{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:45:34Z","timestamp":1788864334025,"version":"build-2803163510"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":1152,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":94,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Entera Bio Ltd."}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The standard treatment of primary hypoparathyroidism (hypoPT) with oral calcium supplementation and calcitriol (or an analog), intended to control hypocalcemia and hyperphosphatemia and avoid hypercalciuria, remains challenging for both patients and clinicians. In 2015, human parathyroid hormone (hPTH) (1-84) administered as a daily subcutaneous injection was approved as an adjunctive treatment in patients who cannot be well controlled on the standard treatments alone. This open-label study aimed to assess the safety and efficacy of an oral hPTH(1-34) formulation as an adjunct to standard treatment in adult subjects with hypoparathyroidism. Oral hPTH(1-34) tablets (0.75\u2009mg human hPTH(1-34) acetate) were administered four times daily for 16 consecutive weeks, and changes in calcium supplementation and alfacalcidol use, albumin-adjusted serum calcium (ACa), serum phosphate, urinary calcium excretion, and quality of life throughout the study were monitored. Of the 19 enrolled subjects, 15 completed the trial per protocol. A median 42% reduction from baseline in exogenous calcium dose was recorded (p\u00a0=\u2009.001), whereas median serum ACa levels remained above the lower target ACa levels for hypoPT patients (&amp;gt;7.5\u2009mg\/dL) throughout the study. Median serum phosphate levels rapidly decreased (23%, p\u00a0=\u2009.0003) 2 hours after the first dose and were maintained within the normal range for the duration of the study. A notable, but not statistically significant, median decrease (21%, p\u00a0=\u2009.07) in 24-hour urine calcium excretion was observed between the first and last treatment days. Only four possible drug-related, non-serious adverse events were reported over the 16-week study, all by the same patient. A small but statistically significant increase from baseline quality of life (5%, p\u00a0=\u2009.03) was reported by the end of the treatment period. Oral hPTH(1-34) treatment was generally safe and well tolerated and allowed for a reduction in exogenous calcium supplementation, while maintaining normocalcemia in adult patients with hypoparathyroidism. \u00a9 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).<\/jats:p>","DOI":"10.1002\/jbmr.4274","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T10:20:46Z","timestamp":1614939646000},"page":"1060-1068","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Safety and Efficacy of Oral Human Parathyroid Hormone (1-34) in Hypoparathyroidism: An Open-Label Study"],"prefix":"10.1093","volume":"36","author":[{"given":"Sofia","family":"Ish-Shalom","sequence":"first","affiliation":[{"name":"Endocrine Research Center Lin Medical Center, Clalit Health Services Haifa Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoseph","family":"Caraco","sequence":"additional","affiliation":[{"name":"Hadassah Medical Center Hebrew University Medical School Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nariman Saba","family":"Khazen","sequence":"additional","affiliation":[{"name":"Endocrine Research Center Lin Medical Center, Clalit Health Services Haifa Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Gershinsky","sequence":"additional","affiliation":[{"name":"Endocrine Research Center Lin Medical Center, Clalit Health Services Haifa Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auryan","family":"Szalat","sequence":"additional","affiliation":[{"name":"Hadassah Medical Center Hebrew University Medical School Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Entera Bio Ltd, Jerusalem Bio Park Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehud","family":"Arbit","sequence":"additional","affiliation":[{"name":"Entera Bio Ltd, Jerusalem Bio Park Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0129-1079","authenticated-orcid":false,"given":"Hillel","family":"Galitzer","sequence":"additional","affiliation":[{"name":"Entera Bio Ltd, Jerusalem Bio Park Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan CY","family":"Tang","sequence":"additional","affiliation":[{"name":"Bioanalytical Facility, Biomedical Research Centre, Norwich Medical School, Faculty of Medicine and Health Sciences University of East Anglia Norwich UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Burshtein","sequence":"additional","affiliation":[{"name":"Entera Bio Ltd, Jerusalem Bio Park Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Rothner","sequence":"additional","affiliation":[{"name":"Entera Bio Ltd, Jerusalem Bio Park Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Raskin","sequence":"additional","affiliation":[{"name":"Entera Bio Ltd, Jerusalem Bio Park Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Blum","sequence":"additional","affiliation":[{"name":"Entera Bio Ltd, Jerusalem Bio Park Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D","family":"Fraser","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology and Clinical Biochemistry Norfolk and Norwich University Hospital Norwich UK"},{"name":"Bioanalytical Facility, Biomedical Research Centre, Norwich Medical School, Faculty of Medicine and Health Sciences University of East Anglia Norwich UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"issue":"12","key":"2024012713481920300_jbmr4274-bib-0001","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/jbmr.2004","article-title":"Prevalence and incidence of hypoparathyroidism in the United States using a large claims database","volume":"28","author":"Powers","year":"2013","journal-title":"J Bone Miner Res."},{"key":"2024012713481920300_jbmr4274-bib-0002","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1210\/jc.2015-3908","article-title":"Epidemiology and diagnosis of hypoparathyroidism","volume":"101","author":"Clarke","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"2024012713481920300_jbmr4274-bib-0003","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1210\/jc.2015-3909","article-title":"Presentation of hypoparathyroidism: etiologies and clinical features","volume":"101","author":"Shoback","year":"2016","journal-title":"J Clin Endocrinol Metabol."},{"key":"2024012713481920300_jbmr4274-bib-0004","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev.med.051308.111339","article-title":"Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23","volume":"61","author":"Bergwitz","year":"2010","journal-title":"Annu Rev Med."},{"key":"2024012713481920300_jbmr4274-bib-0005","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/jbmr.483","article-title":"Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research","volume":"26","author":"Bilezikian","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024012713481920300_jbmr4274-bib-0006","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/jbmr.1484","article-title":"Adverse events from calcium supplementation: relationship to errors in myocardial infarction self-reporting in randomized controlled trials of calcium supplementation","volume":"27","author":"Lewis","year":"2012","journal-title":"J Bone Miner Res."},{"key":"2024012713481920300_jbmr4274-bib-0007","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1359\/jbmr.080803","article-title":"Dynamic and structural properties of the skeleton in hypoparathyroidism","volume":"23","author":"Rubin","year":"2008","journal-title":"J Bone Miner Res."},{"key":"2024012713481920300_jbmr4274-bib-0008","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jbmr.1627","article-title":"Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure","volume":"27","author":"Gafni","year":"2012","journal-title":"J Bone Miner Res."},{"key":"2024012713481920300_jbmr4274-bib-0009","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1210\/jc.2015-3910","article-title":"Management of hypoparathyroidism: present and future","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J Clin Endocrinol Metabol."},{"key":"2024012713481920300_jbmr4274-bib-0010","first-page":"GP25","article-title":"Impact of chronic hypoparathyroidism on health-related quality of life, symptoms, employment, and relationships: findings from a 13-country patient survey","volume":"63","author":"Bollerslev","year":"2019","journal-title":"Endocr Abstracts."},{"key":"2024012713481920300_jbmr4274-bib-0011","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/jbmr.483","article-title":"Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research","volume":"26","author":"Bilezikian","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024012713481920300_jbmr4274-bib-0012","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12020-017-1377-3","article-title":"Quality of life in patients with hypoparathyroidism receiving standard treatment: a systematic review","volume":"58","author":"B\u00fcttner","year":"2017","journal-title":"Endocrine."},{"key":"2024012713481920300_jbmr4274-bib-0013","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"Hypoparathyroid study G: the effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Sikjar","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024012713481920300_jbmr4274-bib-0014","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study","volume":"1","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2024012713481920300_jbmr4274-bib-0015","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00198-009-1149-x","article-title":"Therapy of hypoparathyroidism with intact parathyroid hormone","volume":"21","author":"Rubin","year":"2010","journal-title":"Osteoporos Int."},{"key":"2024012713481920300_jbmr4274-bib-0016","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1210\/jc.2012-2984","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"2024012713481920300_jbmr4274-bib-0017","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/jc.2002-021736","article-title":"Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium","volume":"88","author":"Winer","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"2024012713481920300_jbmr4274-bib-0018","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1210\/jc.2007-2552","article-title":"Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism","volume":"93","author":"Winer","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"2024012713481920300_jbmr4274-bib-0019","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1210\/jc.2009-2464","article-title":"Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1\u201334 versus calcitriol and calcium","volume":"95","author":"Winer","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"2024012713481920300_jbmr4274-bib-0020","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","article-title":"Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism","volume":"276","author":"Winer","year":"1996","journal-title":"JAMA."},{"key":"2024012713481920300_jbmr4274-bib-0021","first-page":"3480","article-title":"A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism","volume":"83","author":"Winer","year":"1998","journal-title":"J Clin Endocrinol Metab."},{"key":"2024012713481920300_jbmr4274-bib-0022","first-page":"391","article-title":"Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism","volume":"97","author":"Winer","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"2024012713481920300_jbmr4274-bib-0023","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jbmr.1627","article-title":"Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure","volume":"27","author":"Gafni","year":"2012","journal-title":"J Bone Miner Res."},{"key":"2024012713481920300_jbmr4274-bib-0024","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jpeds.2014.04.060","article-title":"Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism","volume":"165","author":"Winer","year":"2014","journal-title":"J Pediatr"},{"key":"2024012713481920300_jbmr4274-bib-0025","author":"Burstein"},{"key":"2024012713481920300_jbmr4274-bib-0026","author":"Tang"},{"issue":"4","key":"2024012713481920300_jbmr4274-bib-0027","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/clpt.1994.155","article-title":"Physiologic indirect response models characterize diverse types of pharmacodynamic effects","volume":"56","author":"Jusko","year":"1994","journal-title":"Clin Pharmacol Ther."},{"key":"2024012713481920300_jbmr4274-bib-0028","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/jc.2015-3907","article-title":"Management of hypoparathyroidism: summary statement and guidelines","volume":"101","author":"Brandi","year":"2016","journal-title":"J Clin Endocrinol Metabol."},{"key":"2024012713481920300_jbmr4274-bib-0029","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1210\/jc.2015-4135","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective six year investigation of efficacy and safety","volume":"101","author":"Rubin","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"2024012713481920300_jbmr4274-bib-0030","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1210\/jc.2014-2267","article-title":"PTH (1\u201384) is associated with improved quality of life in hypoparathyroidism through 5\u2009years of therapy","volume":"99","author":"Cusano","year":"2014","journal-title":"J Clin Endocrinol Metabol."},{"key":"2024012713481920300_jbmr4274-bib-0031","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1210\/jc.2015-1855","article-title":"PTH (1\u201334) for surgical hypoparathyroidism: a prospective, open-label investigation of efficacy and quality of life","volume":"100","author":"Santonati","year":"2015","journal-title":"J Clin Endocrinol Metabol."},{"issue":"6","key":"2024012713481920300_jbmr4274-bib-0032","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00223-010-9424-6","article-title":"Pharmacokinetics of teriparatide (rhPTH[1\u201334]) and calcium pharmacodynamics in postmenopausal women with osteoporosis","volume":"87","author":"Satterwhite","year":"2010","journal-title":"Calcif Tissue Int."},{"key":"2024012713481920300_jbmr4274-bib-0033","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.clinthera.2014.04.001","article-title":"Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1\u201384) in patients with hypoparathyroidism: an open-label, single-dose, phase I study","volume":"36","author":"Clarke","year":"2014","journal-title":"Clin Ther."},{"key":"2024012713481920300_jbmr4274-bib-0034","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrd4363","article-title":"Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies","volume":"13","author":"Mitragotri","year":"2014","journal-title":"Nat Rev Drug Discov."},{"key":"2024012713481920300_jbmr4274-bib-0035","volume-title":"Goodman and Gilman's the pharmacological basis of therapeutics","author":"Parker","year":"2005"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.4274","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.4274","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/36\/6\/1060\/55456409\/jbmr4274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/36\/6\/1060\/55456409\/jbmr4274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T11:06:54Z","timestamp":1710328014000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/36\/6\/1060-1068\/7516602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,3,5]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.4274","relation":{"has-review":[{"id-type":"doi","id":"10.1002\/JBMR.4274\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4274\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4274\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4274\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4274\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4274\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4274\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4274\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4274\/v3\/decision1","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,12,1]]},"assertion":[{"value":"2020-09-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}